Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 5/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21025023 | 0.84 | PDK2 (0.45) | PDK2 | |
| SCHEMBL21024768 | 0.84 | PDK2 (0.40) | PDK2ALDH1A1HSD17B10SLC10A2 | |
| SCHEMBL21024765 | 0.83 | MAOA (0.39) | PDK2ALDH1A1 | |
| SCHEMBL21024767 | 0.82 | ALDH1A1 (0.57) | ALDH1A1TSHRMAPK1SMN1; SMN2POLB | |
| SCHEMBL21024764 | 0.81 | PDK2 (0.36) | PDK2ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL22355385 | 0.77 | PDK2 (0.37) | PDK2 | |
| SCHEMBL23805905 | 0.76 | PDK2 (0.43) | PDK2TSHR | |
| SCHEMBL21024766 | 0.76 | PDK2 (0.42) | PDK2ALDH1A1MAPK1SMN1; SMN2KMT2A | |
| SCHEMBL21024763 | 0.76 | PDK2 (0.42) | PDK2ALDH1A1EPHX2 | |
| SCHEMBL22462068 | 0.75 | PDK2 (0.45) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3514135-B1 | FLUORENE PHOTOINITIATOR, PREPARATION METHOD THEREFOR, PHOTOCURABLE COMPOSITION HAVING SAME, AND USE OF SAME IN PHOTOCURING FIELD | CHANGZHOU TRONLY ADVANCED ELECTRONIC MAT CO LTD (CN) | 2021-04-21 | — | — | EP | disclosed |
| US-10976660-B2 | Fluorene photoinitiator, preparation method therefor, photocurable composition having same, and use of same in photocuring field | CHANGZHOU TRONLY ADVANCED ELECTRONIC MATERIALS CO , LTD. (CN) | 2021-04-13 | — | — | US | disclosed |
| EP-3514135-A1 | FLUORENE PHOTOINITIATOR, PREPARATION METHOD THEREFOR, PHOTOCURABLE COMPOSITION HAVING SAME, AND USE OF SAME IN PHOTOCURING FIELD | Changzhou Tronly Advanced Electronic Materials Co., Ltd. (CN) | 2019-07-24 | — | — | EP | disclosed |
| US-20190155153-A1 | Fluorene Photoinitiator, Preparation Method Therefor, Photocurable Composition Having Same, and Use of Same in Photocuring Field | CHANGZHOU TRONLY NEW ELECTRONIC MATERIALS CO., LTD. (CN) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190155153-A1 | Fluorene Photoinitiator, Preparation Method Therefor, Photocurable Composition Having Same, and Use of Same in Photocuring Field | FAR1, AFF1, C1S | PDK2 3423/4885TAS1R3 2563/4885TAS1R1 1486/4885 |
| US-10976660-B2 | Fluorene photoinitiator, preparation method therefor, photocurable composition having same, and use of same in photocuring field | FAR1, AFF1, C1S | PDK2 3423/4885TAS1R3 2563/4885TAS1R1 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.